摘要:
The invention generally relates to compositions and methods for designing and producing functional DNA binding effector molecules and associated customized services, tool kits and functional assays. In some aspects, the invention provides methods and tools for efficient assembly of customized TAL effector molecules. Furthermore, the invention relates to uses of TAL effector molecules and functional evaluation of such TAL by, for example, customized assays.
摘要:
The disclosure relates to recombinant host cells including strain modifications effective to improve titer, yield and/or productivity of fatty acid derivatives. The disclosure further relates to cell cultures including the recombinant host cells for the fermentative production of fatty acid derivatives and compositions thereof.
摘要:
The invention relates to recombinant cells and their use in the production of ethylene glycol. The cells in some embodiments have reduced or eliminated activity or expression of aldehyde dehydrogenase A relative to a wild type cell. In-some embodiments, the aldehyde dehydrogenase A is encoded by an aldA gene, and the cell includes a deletion of the aldA gene.
摘要:
Provided herein are recombinant cells (e.g., recombinant bacteria or plant, insect, mammalian, and yeast cells) containing a nucleic acid encoding a CYP97A protein or a nucleic acid encoding a CYP97B protein; a nucleic acid encoding a CYP97C protein; a nucleic acid encoding a geranylgeranyl pyrophosphate synthase protein; a nucleic acid encoding a phytoene synthase protein; a nucleic acid encoding a phytoene desaturase protein; a nucleic acid encoding a lycopene β-cyclase protein; and a nucleic acid encoding a lycopene ε-cyclase protein. Also provided are methods of producing lutein that include culturing these recombinant cells (e.g., recombinant bacteria and yeast cells), and methods of generating these recombinant cells (e.g., recombinant bacteria and yeast cells). Also provided is lutein produced by these methods, and pharmaceutical compositions, food supplements, food products, and cosmetic compositions that contain lutein produced by these methods.
摘要:
The invention provides a microbial eukaryotic cell capable of utilizing C5 sugars, in particular xylose. Another objective of the invention is to provide an improved protein sequence to enable eukaryotic cells to degrade C5 sugars. The present invention thus provides protein comprising an amino acid sequence having at least 75% identity, preferably 80% identity, most preferably 90 % identity, most highly preferably 95 % identity to SEQ ID NO. 2 or SEQ ID NO. 8 and having xylose-isomerase activity in a eukaryotic cell.
摘要翻译:本发明提供了能够利用C5糖,特别是木糖的微生物真核细胞。 本发明的另一个目的是提供改进的蛋白质序列,以使真核细胞降解C5糖。 因此,本发明提供蛋白质,其包含与SEQ ID NO:具有至少75%同一性,优选80%同一性,最优选90%同一性,最优选95%同一性的氨基酸序列。 2或SEQ ID NO。 8并在真核细胞中具有木糖异构酶活性。
摘要:
The disclosure encompassed herein relates, in part, to a method for increasing energy density of plant biomass that can be used for production of renewable fuel, such as biodiesel oil and/or ethanol. In an aspect, genetic engineering for enhanced sugar accumulation can be achieved by overexpressing a bacterial enzyme sucrose isomerase. Sugars or oils extracted from the plants of the disclosure encompassed herein may be used for industrial purposes such as heating, producing bio-fuels such as biodiesel fuel, or lubricating applications.
摘要:
The disclosure provides attenuated Toxoplasma gondii mutants for use as vaccines or treatment of cancer. More specifically, the attenuated mutants include a knockout mutation of one or more genes of the de novo pyrimidine synthesis pathway, or are generated by gamma-irradiation. Further disclosed are cancers that can be treated with the attenuated mutants.
摘要:
Recombinant microbial cells are provided which have been engineered to produce fatty acid derivatives having linear chains containing an odd number of carbon atoms by the fatty acid biosynthetic pathway. Also provided are methods of making odd chain fatty acid derivatives using the recombinant microbial cells, and compositions comprising odd chain fatty acid derivatives produced by such methods.
摘要:
Die vorliegende Erfindung betrifft neue nicht-zellgängige Cyclosporin-Derivate. Die erfindungsgemäßen Verbindungen finden Verwendung in der Medizin, insbesondere in der Behandlung/Diagnose von akuten und chronischen endzündlichen Erkrankungen, viralen Infektionen, Krebs, degenerativen Muskelerkrankungen, neurodegenerativen Erkrankungen und Schädigungen, welche mit Beeinträchtigung der Calcium- Homöostase einhergehen. Zudem weisen die neuen Cyclosporinderivate keine immunsuppressive Wirkung auf.